Effects of Acute, Rapid Lowering of Low Density Lipoprotein Cholesterol With Alirocumab in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia; Myocardial infarction
- Focus Therapeutic Use
- Acronyms EPIC STEMI
- 14 Mar 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 Planned End Date changed from 15 Sep 2019 to 15 Dec 2019.
- 26 Feb 2019 Planned primary completion date changed from 15 Jun 2019 to 15 Sep 2019.